Home|Journals|Articles by Year|Audio Abstracts

Original Research

RMJ. 2023; 48(4): 805-808

Clinical outcomes in type 2 diabetics switched to Insulin Degludec Aspart from conventional Premixed Insulin therapy

Komal Mumtaz Malik, Kulsoom Farhat, Muhammad Asghar Khan, Bilal Ahmad, Shabana Ali, Mudassar Noor.


Objective: To compare the glycemic control of a newer insulin co-formulation, insulin degludec aspart with the conventional premixed insulin therapy, in type 2 diabetes mellitus.
Methodology: We included 120 participants with documented type 2 diabetes, taking premixed insulin therapy. They were divided into two groups; Group B participants were switched to once-daily insulin degludec aspart whereas those in group A continued receiving biphasic insulin aspart. Glycemic control was assessed with Hemoglobin A1c levels, fasting, and post-prandial plasma glucose concentrations of the participants during a 12-week study period.
Results: HbA1c, Fasting and 2-hour post prandial plasma glucose concentrations were significantly reduced in participants taking insulin degludec aspart (p

Key words: Biphasic insulin aspart, glycemic control, insulin degludec aspart, type 2 diabetes mellitus.

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

ejPort - eJManager.com
Refer & Earn
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.